Clinical Trials
19
Active:0
Completed:3
Trial Phases
3 Phases
Phase 1:13
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (68.4%)Phase 2
4 (21.1%)Phase 3
2 (10.5%)SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: SH-1028 tabletsDrug: Placebo SH-1028 tablets
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT06080776
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
Phase 1
Not yet recruiting
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: SH3765 tablet
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05015309
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: SH3809 tablet
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT04843033
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C] SH-1028
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04810533
- Locations
- 🇨🇳
Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine, Nanjing, Jiangsu, China
The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028
Phase 1
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04808648
- Locations
- 🇨🇳
the First Affiliated Hospital with Bengbu Medical College, Bengbu, Anhui, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found